Diagnosis of Alport syndrome - Search for proteomic biomarkers in body fluids

Pediatric Nephrology

Volumn 28, Issue 11, 2013, Pages 2117-2123

  Pohl, Michael ^a   Danz, Karin ^b   Gross, Oliver ^c   John, Ulrike ^a   Urban, Johannes ^d   Patzer, Ludwig ^e   Habbig, Sandra ^f   Feldkötter, Markus ^f   Witzke, Oliver ^g   Walther, Mario ^b   Rhode, Heidrun ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d Josefinum   (Germany)

^e MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^f UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^g UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

ADAM8; Fibronectin; Matrix metalloproteinase; Myosin; Podocin

Indexed keywords

ADAM PROTEIN; BIOLOGICAL MARKER; COLLAGEN TYPE 1; COLLAGEN TYPE 4; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISINTEGRIN; FIBRONECTIN; GELATINASE A; GELATINASE B; HEMOPEXIN; MYOSIN 10; MYOSIN 9; NEPHRIN; PODOCALYXIN; PODOCIN; SYNAPTOPODIN; UNCLASSIFIED DRUG;

ALPORT SYNDROME; ARTICLE; BODY FLUID; CLINICAL ASSESSMENT; CONTROLLED STUDY; EARLY DIAGNOSIS; ENZYME INHIBITION; GENETIC ANALYSIS; HUMAN; IMMUNOASSAY; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEOMICS;

ADAM PROTEINS; BIOLOGICAL MARKERS; FIBRONECTINS; HUMANS; IMMUNOASSAY; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEMBRANE PROTEINS; MYOSINS; NEPHRITIS, HEREDITARY; PROTEOMICS;

EID: 84885960796     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-013-2533-5     Document Type: Article

References (30)

1. Gubler MC (2008) Inherited diseases of the glomerular basement membrane. Nat Clin Pract Nephrol 4:24-37
2. Hertz JM (2009) Alport syndrome. Molecular genetic aspects. Dan Med Bull 56:105-152
3. Gross O, Netzer KO, Lambrecht R, Seibold S, Weber M (2003) Novel COL4A4 splice defect and in-frame deletion in a large consanguine family as a genetic link between benign familial haematuria and autosomal Alport syndrome. Nephrol Dial Transplant 18:1122-1127
4. Arrondel C, Deschenes G, Le Meur Y, Viau A, Cordonnier C, Fournier A, Amadeo S, Gubler MC, Antignac C, Heidet L (2004) A large tandem duplication within the COL4A5 gene is responsible for the high prevalence of Alport syndrome in French Polynesia. Kidney Int 65:2030-2040
5. Liapis H, Gokden N, Hmiel P, Miner JH (2002) Histopathology, ultrastructure, and clinical phenotypes in thin glomerular basement membrane disease variants. Hum Pathol 33:836-845
6. Hertz JM, Thomassen M, Storey H, Flinter F (2012) Clinical utility gene card for: Alport syndrome. Eur J Hum Genet. doi: 10.1038/ejhg.2011.237
7. Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, Weber M, Gross O, Netzer KO, Flinter F, Pirson Y, Verellen C, Wieslander J, Persson U, Tryggvason K, Martin P, Hertz JM, Schroder C, Sanak M, Krejcova S, Carvalho MF, Saus J, Antignac C, Smeets H, Gubler MC (2000) X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol 11:649-657
8. Pescucci C, Mari F, Longo I, Vogiatzi P, Caselli R, Scala E, Abaterusso C, Gusmano R, Seri M, Miglietti N, Bresin E, Renieri A (2004) Autosomal-dominant Alport syndrome: natural history of a disease due to COL4A3 or COL4A4 gene. Kidney Int 65:1598-1603
9. Rizk D, Chapman AB (2003) Cystic and inherited kidney diseases. Am J Kidney Dis 42:1305-1317
10. Kashtan CE, Segal Y (2011) Genetic disorders of glomerular basement membranes. Nephron Clin Pract 118:c9-c18
11. Hicks J, Mierau G, Wartchow E, Eldin K (2012) Renal diseases associated with hematuria in children and adolescents: a brief tutorial. Ultrastruct Pathol 36:1-18
12. Rheault MN, Kren SM, Hartich LA, Wall M, Thomas W, Mesa HA, Avner P, Lees GE, Kashtan CE, Segal Y (2010) X-inactivation modifies disease severity in female carriers of murine X-linked Alport syndrome. Nephrol Dial Transplant 25:764-769
13. Kashtan CE (2004) Familial hematuria due to type IV collagen mutations: Alport syndrome and thin basement membrane nephropathy. Curr Opin Pediatr 16:177-181
14. Zhou W, Hirsch M, Junk AK, Casper DS, Braunstein R, David J, Worgul BV (2003) Evaluation of lenticonus in Alport's syndrome: quantitative Scheimpflug analysis. Ophthalmologica 217:189-193
15. Gubler MC (2007) Diagnosis of Alport syndrome without biopsy? Pediatr Nephrol 22:621-625
16. Thorner PS (2007) Alport syndrome and thin basement membrane nephropathy. Nephron Clin Pract 106:c82-c88
17. Kashtan CE, Ding J, Gregory M, Gross O, Heidet L, Knebelmann B, Rheault M, Licht C (2013) Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatr Nephrol 28:5-11
18. Webb NJ, Lam C, Shahinfar S, Strehlau J, Wells TG, Gleim GW, Le Bailly De Tilleghem C (2011) Efficacy and safety of losartan in children with Alport syndrome-results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial. Nephrol Dial Transplant 26:2521-2526
19. Cosgrove D (2012) Glomerular pathology in Alport syndrome: a molecular perspective. Pediatr Nephrol 27:885-890
20. Gross O, Beirowski B, Koepke ML, Kuck J, Reiner M, Addicks K, Smyth N, Schulze-Lohoff E, Weber M (2003) Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 63:438-446
21. Grodecki KM, Gains MJ, Baumal R, Osmond DH, Cotter B, Valli VE, Jacobs RM (1997) Treatment of X-linked hereditary nephritis in Samoyed dogs with angiotensin converting enzyme (ACE) inhibitor. J Comp Pathol 117:209-225
22. Gross O, Licht C, Anders HJ, Hoppe B, Beck B, Tonshoff B, Hocker B, Wygoda S, Ehrich JH, Pape L, Konrad M, Rascher W, Dotsch J, Muller-Wiefel DE, Hoyer P, Study Group Members of the Gesellschaft fur Padiatrische N, Knebelmann B, Pirson Y, Grunfeld JP, Niaudet P, Cochat P, Heidet L, Lebbah S, Torra R, Friede T, Lange K, Muller GA, Weber M (2012) Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 81:494-501
23. Gross O, Friede T, Hilgers R, Gorlitz A, Gavenis K, Ahmed R, Durr U (2012) Safety and efficacy of the ACE-inhibitor ramipril in Alport syndrome: The Double-Blind, Randomized, Placebo-Controlled. Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients ISRN Pediatr 2012:436046 doi: 10.5402/2012/436046
24. Lubec G, Balzar E, Weissenbacher G, Syré G (1978) Urinary excretion of glomerular basement membrane antigens in Alport's syndrome. A new diagnostic approach. Arch Dis Child 53:401-406
25. Lubec G, Legenstein E, Meznik E (1980) Harnausscheidung von sauren Glykosaminoglykanen und Glomerulumbasalmembranantigenen bei Patienten mit Alport Syndrom. Klin Pädiatr 192:453-456
26. Baum A, Pohl M, Kreusch S, Cumme GA, Ditze G, Misselwitz J, Kiehntopf M, Udby L, Meier-Hellmann A, Rhode H (2008) Searching biomarker candidates in serum using multidimensional native chromatography. II Method evaluation with Alport syndrome and severe inflammation. J Chromatogr B Analyt Technol Biomed Life Sci 876:31-40
27. White JM (2003) ADAMs: modulators of cell-cell and cell-matrix interactions. Curr Opin Cell Biol 15:598-606
28. Dreymueller D, Pruessmeyer J, Groth E, Ludwig A (2012) The role of ADAM-mediated shedding in vascular biology. Eur J Cell Biol 91:472-485
29. Noone D, Licht C (2012) An update on the pathomechanisms and future therapies of Alport syndrome. Pediatr Nephrol 28:1025-1036
30. McKnight AJ, Currie D, Maxwell AP (2010) Unravelling the genetic basis of renal diseases; from single gene to multifactorial disorders. J Pathol 220:198-216